257 Secukinumab demonstrates a consistent safety profile with up to 5 years’ treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses
Rheumatology（2019）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined